Market closed
SpringWorks/$SWTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About SpringWorks
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Ticker
$SWTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
305
Website
SpringWorks Metrics
BasicAdvanced
$2.6B
Market cap
-
P/E ratio
-$3.83
EPS
0.79
Beta
-
Dividend rate
Price and volume
Market cap
$2.6B
Beta
0.79
52-week high
$53.92
52-week low
$28.21
Average daily volume
1.4M
Financial strength
Current ratio
6.162
Quick ratio
5.801
Long term debt to equity
1.067
Total debt to equity
1.297
Management effectiveness
Return on assets (TTM)
-34.28%
Return on equity (TTM)
-59.33%
Valuation
Price to revenue (TTM)
18.88
Price to book
4.97
Price to tangible book (TTM)
4.97
Price to free cash flow (TTM)
-11.567
Growth
Earnings per share change (TTM)
-21.72%
3-year revenue growth (CAGR)
57.02%
3-year earnings per share growth (CAGR)
20.03%
What the Analysts think about SpringWorks
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for SpringWorks stock.
SpringWorks Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SpringWorks Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SpringWorks News
AllArticlesVideos
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Seeking Alpha·1 week ago
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
GlobeNewsWire·4 weeks ago
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for SpringWorks stock?
SpringWorks (SWTX) has a market cap of $2.6B as of December 23, 2024.
What is the P/E ratio for SpringWorks stock?
The price to earnings (P/E) ratio for SpringWorks (SWTX) stock is 0 as of December 23, 2024.
Does SpringWorks stock pay dividends?
No, SpringWorks (SWTX) stock does not pay dividends to its shareholders as of December 23, 2024.
When is the next SpringWorks dividend payment date?
SpringWorks (SWTX) stock does not pay dividends to its shareholders.
What is the beta indicator for SpringWorks?
SpringWorks (SWTX) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.